title: Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.
authors.affiliation: Department of Medicine, Section of Vascular Medicine, University of Colorado Health Sciences Center, Colorado Prevention Center, and National Jewish Medical and Research Center, Denver, 80203, USA.
authors.forename: Eric P
authors.initials: EP
authors.lastname: Brass
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Lewis
authors.forename: Raymond
authors.initials: R
authors.lastname: Lipicky
authors.forename: James
authors.initials: J
authors.lastname: Murphy
authors.forename: William R
authors.initials: WR
authors.lastname: Hiatt
mesh_terms: D000465:Algorithms; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D000077407:Cilostazol; D006801:Humans; D018570:Risk Assessment; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D002317:Cardiovascular Agents; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol